Loading...
Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
Coombes, R. C. Badman, P. D. Lozano-Kuehne, J. P. Liu, X. Macpherson, I. R. Zubairi, I. Baird, R. D. Rosenfeld, N. Garcia-Corbacho, J. Cresti, N.
Coombes, R. C.
Badman, P. D.
Lozano-Kuehne, J. P.
Liu, X.
Macpherson, I. R.
Zubairi, I.
Baird, R. D.
Rosenfeld, N.
Garcia-Corbacho, J.
Cresti, N.
Citations
Altmetric:
Abstract
Description
Date
2023
Publisher
Collections
Files
Keywords
Type
Other
Citation
Coombes RC, Badman PD, Lozano-Kuehne JP, Liu X, Macpherson IR, Zubairi I, et al. Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. Nature communications. 2023 Jan 17;14(1):260. PubMed PMID: 36650166. Pubmed Central PMCID: PMC9845345. Epub 2023/01/18. eng.